The zero hour for the comment submissions on the biosimilar labeling draft guidance has passed, with both innovator and generic drug groups pulling FDA in opposite directions over issues related to the inclusion of clinical data and the agency's proposed statement on biosimilarity.
With the last string of industry comments coming in by the Aug
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?